HBV相关失代偿期肝硬化启动抗病毒治疗后再代偿的决定因素
本研究纳入311例接受恩替卡韦或替诺福韦治疗的HBV相关失代偿期肝硬化患者,以Child-Pugh评分恢复至5分为再代偿标准,基于竞争风险模型建立BC2AID评分并在验证队列中评估。BC2AID评分预测1年内再代偿的AUC为0.813,显著高于Child-Pugh、MELD、MELDNa和BE3A评分。
要点
- BC2AID评分由6项独立预测因子构成,可预测启动强效NUC治疗后1年内再代偿。
- 验证队列中BC2AID评分AUC为0.813,优于Child-Pugh、MELD、MELDNa和BE3A评分。
- 从初次失代偿至启动NUCs≤6个月与再代偿独立相关(aSHR 4.79)。
核心结论
- 包含AFP和抗病毒治疗时机的6项临床参数组合成评分系统,可准确预测HBV相关失代偿期肝硬化患者的早期再代偿。
研究设计与样本
- 分析311例连续接受恩替卡韦或替诺福韦治疗的HBV相关失代偿期肝硬化患者,主要结局为再代偿(恢复至Child-Pugh评分5分)。
- BC2AID评分基于竞争风险模型在152例推导队列中建立,并在另159例验证队列中验证。
主要发现
- 推导队列和验证队列中再代偿发生率分别为57.2%和66.7%。
- 推导队列识别出6项再代偿独立预测因子:胆红素≤5 mg/dL(aSHR 2.18)、无严重并发症(aSHR 2.78)、AFP≥50 ng/mL(aSHR 2.54)、ALT≥200 IU/L(aSHR 2.62)、INR≤1.5(aSHR 2.37)、从初次失代偿至启动NUCs≤6个月(aSHR 4.79)。
- 验证队列中BC2AID评分预测NUC治疗1年内再代偿的AUC为0.813,显著高于Child-Pugh(0.691)、MELD(0.638)、MELDNa(0.645)和BE3A(0.624)评分,均P<0.05。
关键数值与推荐
- 再代偿定义为恢复至Child-Pugh评分5分。
- BC2AID评分包含:胆红素≤5 mg/dL、无严重并发症、AFP≥50 ng/mL、ALT≥200 IU/L、INR≤1.5、从初次失代偿至启动NUCs≤6个月。
- 验证队列中BC2AID评分预测1年内再代偿AUC为0.813,Child-Pugh为0.691,MELD为0.638,MELDNa为0.645,BE3A为0.624,均P<0.05。
临床怎么用
- 对HBV相关失代偿期肝硬化启动强效NUC治疗的患者,可用BC2AID评分评估1年内再代偿可能性。
- BC2AID评分包含AFP和抗病毒治疗时机等参数,有助于识别早期再代偿概率较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite antiviral therapy, liver function often fails to recover in patients with hepatitis B virus (HBV)-related decompensated cirrhosis. AIM: To establish a prognostic model to predict re-compensation in patients starting potent nucleos(t)ide analogue (NUC) therapy METHODS: We analysed 311 consecutive patients with HBV-related decompensated cirrhosis treated with entecavir or tenofovir. The primary outcome was re-compensation, defined as recovery to a Child-Pugh score of 5. The BC2AID score was developed from a cohort of 152 subjects based on competing risk models and validated in another cohort of 159 subjects. RESULTS: Re-compensation occurred in 57.2% and 66.7% of the subjects in the derivation and validation cohorts, respectively. Six independent predictors for re-compensation were identified in the derivation cohort and these comprised the BC2AID score: bilirubin ≤5 mg/dL (adjusted sub-distribution hazard ratio [aSHR] 2.18), absence of severe complications (aSHR 2.78), alpha-fetoprotein (AFP) ≥50 ng/mL (aSHR 2.54), alanine aminotransferase ≥200 IU/L (aSHR 2.62), international normalised ratio ≤1.5 (aSHR 2.37) and ≤6 months from initial decompensation until initiation of NUCs (aSHR 4.79). In the validation cohort, the area under the receiver operating characteristic curve of the BC2AID score for re-compensation within 1 year of NUC therapy was significantly higher than that of the Child-Pugh, MELD, MELDNa and BE3A scores (0.813 vs 0.691, 0.638, 0.645 and 0.624, respectively; all P < 0.05). CONCLUSIONS: Six clinical parameters, including AFP and the timing of antiviral therapy, were combined into a scoring system to accurately predict early re-compensation in patients with HBV-related decompensated cirrhosis.
引用
- Kim TH, Um SH, Lee YS, et al. Determinants of re-compensation in patients with hepatitis B virus-related decompensated cirrhosis starting antiviral therapy. Aliment Pharmacol Ther. 2021. PMID: 34662436. doi:10.1111/apt.16658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。